Demand has broadened across independent fronts: growth is now coming from several distinct, currently-producing sources
The model's full reasoning — Q4 2022 call → NOWe need to determine if management describes current growth being carried by several distinct, independent sources at the same time, each already producing real current business, and that this breadth is recent or building. The transcript mentions MRD business with clonoSEQ clinical volumes, MRD pharma partnerships, and also immune medicine with pharma services and drug discovery. But are these described as distinct engines? The company has two business areas: MRD and Immune Medicine. Within MRD, there is clinical testing and pharma partnerships. Within Immune Medicine, there is pharma services and drug discovery (Genentech collaboration). However, the question asks for at least three genuinely different engines. The transcript mentions MRD clinical testing, MRD pharma partnerships, and immune medicine pharma services, and also drug discovery (Genentech). But are these described as currently producing real business? Yes, they have revenue. But is the breadth recent? The company reorganized into two business areas in 2022, but they have been operating in these areas for a while. The transcript says "2022 was a year of key decisions and achievements" and they set strategic goals. They mention growth in MRD clinical volumes, MRD pharma partnerships, and pharma services. However, the question asks if management conveys that the company was until recently narrower, with growth carried by fewer engines. The transcript does not explicitly say that. It says they reorganized, but that doesn't necessarily mean they were narrower. Also, the drug discovery is still in development, not yet producing revenue from products, but the Genentech collaboration has milestones and amortization. But the question says "each of which is described as ALREADY PRODUCING REAL CURRENT BUSINESS" - drug discovery is not yet producing revenue from products, but the collaboration has amortization and milestones. However, the transcript mentions "Pharma services had substantial growth of 67% versus 2021." And MRD clinical volumes grew 51%. And MRD pharma partnerships also grew. So there are multiple revenue streams. But are they described as distinct engines? The company has two business areas, but within MRD there are two: clinical and pharma. Within immune medicine, there is pharma services and drug discovery.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| E | Eni S.p.A. | Q1 2024 | 2024-04-24 | B+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| PSFE | Paysafe Limited | Q4 2023 | 2024-03-07 | C+ |
| FRPH | FRP Holdings, Inc. | Q4 2023 | 2024-03-07 | C+ |
| GTLB | GitLab Inc. | Q4 2024 | 2024-03-04 | C+ |
| INTR | Inter & Co, Inc. | Q4 2023 | 2024-02-08 | B+ |
| TBLA | Taboola.com Ltd. | Q3 2023 | 2023-11-08 | B+ |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| ANGO | AngioDynamics, Inc. | Q1 2024 | 2023-10-04 | B |
| CTLP | Cantaloupe, Inc. | Q4 2023 | 2023-09-06 | B+ |
| KMDA | Kamada Ltd. | Q2 2023 | 2023-08-16 | B+ |
| ZOM | Zomedica Corp. | Q2 2023 | 2023-08-10 | C |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| INTT | inTEST Corporation | Q2 2023 | 2023-08-04 | A |
| FOUR | Shift4 Payments, Inc. | Q2 2023 | 2023-08-03 | B+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| PERI | Perion Network Ltd. | Q2 2023 | 2023-08-02 | A |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| EDU | New Oriental Education & Technology Grou | Q3 2023 | 2023-04-19 | B |
| ISRG | Intuitive Surgical, Inc. | Q4 2022 | 2023-01-24 | C |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| GDRX | GoodRx Holdings, Inc. | Q2 2022 | 2022-08-08 | F |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| UGRO | urban-gro, Inc. | Q1 2022 | 2022-05-13 | D |
| XMTR | Xometry, Inc. | Q1 2022 | 2022-05-11 | B+ |
| CLAR | Clarus Corporation | Q1 2022 | 2022-05-09 | B |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| ABNB | Airbnb, Inc. | Q1 2022 | 2022-05-03 | B+ |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| WSC | WillScot Mobile Mini Holdings Corp. | Q4 2021 | 2022-02-25 | B+ |
| LMND | Lemonade, Inc. | Q4 2021 | 2022-02-24 | D |
| SNOW | Snowflake Inc. | Q3 2022 | 2021-12-01 | A |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| ZH | Zhihu Inc. | Q3 2021 | 2021-11-22 | D |
| BRAG | Bragg Gaming Group Inc. | Q3 2021 | 2021-11-08 | B+ |
| ENV | Envestnet, Inc. | Q3 2021 | 2021-11-08 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| IPGP | IPG Photonics Corporation | Q3 2021 | 2021-11-02 | C |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| CROX | Crocs, Inc. | Q3 2021 | 2021-10-21 | B+ |
| DG | Dollar General Corporation | Q2 2021 | 2021-08-26 | A |
| ZIM | ZIM Integrated Shipping Services Ltd. | Q2 2021 | 2021-08-18 | B+ |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| Z | Zillow Group, Inc. | Q2 2021 | 2021-08-05 | B |
| NOV | NOV Inc. | Q2 2021 | 2021-07-28 | C+ |
| STRA | Strategic Education, Inc. | Q2 2021 | 2021-07-28 | C |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| AMGN | Amgen Inc. | Q3 2018 | 2018-10-30 | B+ |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| BCO | The Brink's Company | Q3 2018 | 2018-10-24 | C |
| NDLS | Noodles & Company | Q3 2018 | 2018-10-23 | B+ |
| AUDC | AudioCodes Ltd. | Q3 2018 | 2018-10-23 | A |
| YEXT | Yext, Inc. | Q2 2019 | 2018-08-30 | C+ |
| TNC | Tennant Company | Q2 2018 | 2018-07-25 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C+ |
| ST | Sensata Technologies Holding plc | Q2 2017 | 2017-07-25 | B+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| HUBB | Hubbell Incorporated | Q2 2017 | 2017-07-25 | B+ |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| PPSI | Pioneer Power Solutions, Inc. | Q4 2016 | 2017-03-10 | B |
| ABR | Arbor Realty Trust, Inc. | Q4 2016 | 2017-03-03 | B+ |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| LGND | Ligand Pharmaceuticals Incorporated | Q4 2016 | 2017-02-23 | C+ |
| PYPL | PayPal Holdings, Inc. | Q4 2016 | 2017-01-26 | B+ |
| PNFP | Pinnacle Financial Partners, Inc. | Q2 2016 | 2016-07-20 | B |
| BX | Blackstone Inc. | Q1 2016 | 2016-04-21 | B |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
GDRX · Q2 2022 → YESThe question is about whether management describes the company's CURRENT growth as being carried by SEVERAL DISTINCT, INDEPENDENT SOURCES AT THE SAME TIME — at least three genuinely different engines,...YES The transcript shows management describing current growth as carried by multiple distinct engines: prescription transactions (still the core but with recent challenges), subscriptions revenue (82% YoY growth), and Pharma Manufacturer Solutions (more than doubled YoY). They explicitly frame the diversification as a recent development, noting that other offerings now make up 30% of revenue compared to 5% just three years ago, with several sources like subscriptions and pharma still having most of their contribution ahead due to significant TAM and low penetration. This breadth is presented as newly meaningful for the company, reflecting the early stage of these newer fronts rather than a long-standing diversified business.
TOUR · Q4 2017 → YESThe question is about whether management describes current growth being carried by several distinct, independent sources at the same time — at least three genuinely different engines — each already pr...YES Management describes current growth as carried by multiple distinct, independent engines that are already producing real revenue and activity: packaged tours (organized and self-guided), financial services and commissions, offline retail stores (18% of GMV in Q4 2017, launched 2016), direct procurement (40% of GM 2017), and corporate TMC services (more than 200% YoY growth). They explicitly note diversification of sales channels (online, mobile, loyalty, offline, B2B/corporate) and that the company was narrower until recently, with offline retail and corporate TMC expanding in 2016–2017 while local operators remain small but growing.
CYBR · Q3 2021 → YESThe question is about whether management describes current growth being carried by several distinct, independent sources at the same time — at least three genuinely different engines — each producing ...YES The transcript shows management describing current growth as driven by multiple distinct, independent engines operating simultaneously: record SaaS bookings and subscription ARR growth (131%), the Identity Security platform centered on Privileged Access Management (PAM) and Privilege Cloud with new logos over 230, EPM with another record quarter, Access and DevSecOps offerings, plus expansion across geographies (every region growing) and verticals (new logos in law firms, software, oil & gas, retailers, government). These are presented as real, current business with concrete metrics and customer examples, not plans.